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Background: Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia.
Adverse reactions to clozapine include neutropenia. In March 2020, at the start of the Coronavirus 19 pandemic,
clinicians raised concerns regarding continuation of antipsychotic treatment, and specifically of clozapine, in
patients with coronavirus disease. We aimed here at providing a short report focusing on the association between
neutropenia and clozapine in a case series of psychiatric inpatients diagnosed with COVID-19.
Patients & methods: We retrospectively inspected data of 10 patients on clozapine, admitted to Highgate Mental
Health Centre, Camden & Islington NHS Foundation Trust, between March and July 2020; selection was based on
their COVID-19 positive PCR test. We used a linear regression model to estimate whether there was a significant
drop in the neutrophil count during SARS-CoV-2 infection.
The analysis was done in R using a linear regression to the origin.
Results: Data were collected on 10 patients, of which 7 were males. During COVID-19 infection, neutrophils’ count
(ANC) was 4.13  109/l (SD ¼ 2.70) which constituted a significant drop from a baseline value of 5.2  109/l (SD
¼ 2.24). The mean relative reduction in ANC was 0.2729 (SD ¼ 0.1666). The beta value of 0.8377 obtained with
the linear regression showed that ANC values during SARS-CoV-2 infection were 83.77% of the baseline ANC
showing that within the two time points there was a decrease of 16.23%. The linear regression had a pvalue ¼
8.96  10–8 and an adjusted R2 of 95.94% which shows that the variability of the data is very well explained by
the model. We also compared baseline ANC with ANC values approximately a month after resolution of the
infection and results indicate that ANC values return to a 95% of baseline.
Conclusions: Clinicians should bear in mind that a significant drop in neutrophils’ count may occur in patients
taking clozapine and affected from a SARS-CoV-2 infectionand that this drop is only transitory.1. Background
Clozapine is amongst the most effective antipsychotics used for
treatment-resistant schizophrenia (Huhn et al., 2019). Clozapine remains
significantly underutilized, in part due to frequent blood tests requiring
regular absolute neutrophil count (ANC) monitoring (Nichols et al.,
2020). Adverse reactions to clozapine include neutropenia (2.7% of pa-
tients) which can prefigure an impending life-threateningCentre, Camden & Islington NHS
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23 January 2021; Accepted 23
is an open access article under tagranulocytosis, (0.4% of patients) (Atkin et al., 1996; Gee and Taylor,
2020; Pandarakalam, 2020). Clozapine treatment is also associated with
diabetes, obesity, pulmonary disease (Gee et al., 2020; Dragoi et al.,
2020) and a reported increased risk of COVID-19 infection (Govind et al.,
2020). Switching to an alternative antipsychotic in patients clinically
stable on clozapine is challenging, both for clinicians and patients, as this
strategy is associatedwith a high risk of relapse due to the high likelihood
of patients who have required treatment with clozapine being resistant toFoundation Trust, Dartmouth Park Hill, N19 5 NX, UK.
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Fig. 1. Absolute Neutrophils Count (ANC) and White Cell Count (WCC) pre-,
during, and after SARS-CoV-2 infection in patients taking clozapine. Baseline is
S. Bonaccorso et al. Brain, Behavior, & Immunity - Health 13 (2021) 100212treatment with other antipsychotics (Butler et al., 2020; Chiappini et al.,
2020).
In March 2020, at the start of the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) pandemic, clinicians raised concerns
regarding continuation of antipsychotic treatment, and specifically of
clozapine, in patients with coronavirus disease (COVID-19) (Boland and
Dratcu, 2020). Initially the information emerging from the Chinese
experience (Guan et al., 2020) indicated that COVID-19 was linked to
lymphopenia but not neutropenia (Gee et al., 2020), and that neutrophils
were in the normal range (Huang et al., 2020; Chen et al., 2020; Wang
et al., 2020). Case series from around the same period also reported that
clozapine-treated patients with COVID-19 symptoms and/or who tested
positive to SARS-CoV-2 presented with no documented neutropenia and
no statistically significant changes in ANC (Butler et al., 2020; Gee and
Taylor, 2020). Furthermore, clinicians were provided with practical
recommendations (Gee et al., 2020; Ostuzzi et al., 2020) and advised to
continue clozapine treatment in patients with COVID-19 when indicated
(Gee et al., 2020; Boland and Dratcu, 2020; Butler et al., 2020).
We aimed here at providing a short report focusing on the association
between neutropenia and clozapine in a case series of psychiatric in-
patients diagnosed with COVID-19.
2. Patients and methods
We retrospectively inspected data relating to patients admitted to
Highgate Mental Health Centre, Camden & Islington NHS Foundation
Trust, between March and July 2020. Data were anonymised for the
purposes of this evaluation. Patients on clozapine who had COVID-19
symptoms and a positive SARS-CoV-2 PCR test were included. We
collected the white cell count (WCC) and the ANC at three different time
points: (1) baseline, (2) during SARS-CoV-2 infection and (3) post- SARS-
CoV-2 infection. The baseline was an average of thecounts of the previous
three years. The second time point was taken during COVID-19 infection
with a mean of 3 days (SD¼ 2.83), a median of 3 and a mode of 2.67 days
after onset of symptoms; and the third and final time point was approx-
imately a month after a positive SARS-CoV-2 PCR test (depending on the
availability of blood sample) with a mean of 53 days (SD ¼ 50.51), a
median of 30 and a mode of 26 days. An ethics’ application to the NHS
Health Research Authority Tool was made; no further approval was
required since this report was felt to be part of a service evaluation.
We compared the baseline ANC (ANCbaselineÞ with the ANC during
SARS-CoV-2 (ANCSARSCoV2) to see whether there was a drop between
the two and whether this drop was significant. We did so by using a linear
regression model where the dependent variable was the ANCSARSCoV2
and the independent variable was the ANCbaseline. If there was no differ-
ence between the two, the linear model would indicate a slope (β) of 1.
Alternatively, the model would indicate a slope less than 1 if
ANCSARSCoV2 was less than ANCbaseline. Subsequently, we used the same
methodology to describe (1) the difference between ANCbaseline and the
ANC obtained after resolution of the SARS-CoV-2 infection (ANCpost) and
(2) to describe the difference between ANCSARSCoV2 and ANCpost . The
analysis was done in R (R Core Team, 2020), using a simple linear
regression to the origin. We have made the data and the code available to
the editor and it can be requested by contacting the corresponding author
directly.
3. Results
Data were collected on 10 patients, of which 7 were males. Their
median age was 45.44 years. Regarding their ethnic origin, 5 subjects
were of African descent, 2 were Asian and 3 were Caucasian. The patients
had been diagnosed according to the ICD-10 and the most prevalent
diagnosis was that of Schizophrenia, which was the diagnosis for 8 pa-
tients; 1 patient had Schizoaffective disorder and one patient had
Emotionally Unstable Personality Disorder. In terms of comorbidities2
documented prior to SARS-CoV-2 infection, 2 subjects had chronic
obstructive pulmonary disease, 4 had diabetes mellitus, 4 had dyslipi-
demia and 2 had hypertension. One patient had an estimated glomerular
filtration rate of less than 60 mL/min. One patient had chronic hepatitis
B. Three patients were smokers, none had alcohol or substance misuse.
One patient had benign ethnic neutropenia (BEN).
All subjects developed COVID-19 symptoms between March and July
2020. All of them tested positive for SARS-CoV-2. Patients were all on
clozapine and under the Clozapine Patient Monitoring System (CPMS).
The mean duration of clozapine treatment was of 726.1 days prior to the
date of sample collection during COVID-19 infection. Patients were
receiving doses of clozapine ranging from 200 to 600 mg OD. The dose
was decreased in one patient during the infection and for another patient
clozapine was stopped. For most patients the course of the SARS-CoV-2
infection was uncomplicated except for one who required an intensive
care unit admission and intubation.
During SARS-CoV-2 infection, the mean WCC increased to 6.08 
109/l (SD ¼ 2.71) from a baseline value of 5.64  109/l (SD ¼ 1.73).
Concurrently, the ANC dropped significantly to 4.13 109/l (SD ¼ 2.70)
from a baseline value of 5.2  109/l (SD ¼ 2.24) (see Fig. 1). The mean
relative reduction in ANC was 0.2729 (SD ¼ 0.1666). The mean WCC
after SARS-CoV-2 infection was of 7.49 109/l (SD ¼ 2.58) and the ANC
was of 5.28  109/l (SD ¼ 2.14).
The linear regression withANCSARSCoV2 as a dependent variable and
ANCbaseline as an independent variable can be explained by the following
equation:
ANCSARSCoV2 ¼ 0:8377 ANCbaseline þ 0
The β value of 0.8377 obtained with this linear regression showed
that ANC values during SARS-CoV-2 infection were 83.77% of the
baseline ANC. This provides a measurement of the drop that occurred
between the two timepoints showing a decrease in ANC of 16.23%. This
linear regression had a p-value ¼ 8.96  108 and an adjusted R2 of
95.94% which shows that the variability of the data is very well
explained by the model.
The second linear regression uses ANCpost as the dependent variable
and ANCSARSCov2 as the independent variable. The relationship be-
tween the two is explained by the following equation:
ANCpost ¼ 1:0638 ANCSARSCoV2 þ 0
This β value is higher than 1 and therefore shows an increase in the
ANC between the time of infection and after the infection. This increase is
of 6.38%. The linear regression has a p-value ¼ 8.32  105 and an
adjusted R2 of 81.7%.
Finally, we compared the baseline ANC with the ANC after resolution
of the infection. Their relationship is explained by the following equa-an average of ANC and WCC values of previous 3 years.
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ANCpost ¼ 0:95029 ANCbaseline þ 0
The equation shows that ANCpost is 95.029% of the ANCbaseline with a
significant drop of 4.97% for the ANCpost when compared to ANCbaseline .
The model has a p-value ¼ 4.06  106 and an adjusted R2 of 90.57%.
4. Discussion
This is the first report suggesting the occurrence of a significant drop
in ANC in patients taking clozapine whilst infected with SARS-CoV-2
infection. In these patients the drop was transitory and was followed
by an increase in the ANC that reached values close to baseline after
resolution of coronavirus disease. It is noteworthy that, in 3 patients the
ANC drop resulted in a change of monitoring status from ‘green’ to
‘amber,’ (CPMS thresholds) so that more frequent blood tests were
required. However, these 3 patients’ amber status changed back to green,
with an ANC normalization, when SARS-CoV-2 infection resolved.
In essence, these results show that, in patients with COVID-19 taking
clozapine, ANC values initially decline by 17% from baseline; but sub-
sequently increase again to around 95% of the pre-infection values
following resolution of the infection. Furthermore, all patients, including
the 3 who had ‘amber’ results whilst infected with COVID- 19 achieved
‘green’ results approximately three months after the resolution of the
infection.
These results are of considerable clinical importance for clinicians
and patients as they give reassurance about continuing clozapine treat-
ment during COVID-19 illness – when this is clinically indicated. We are
aware of limitations of current report and in particular the fact that our
case series included only 10 patients. We therefore advocate for studies
with a larger sample size and a control group.
We also offer below a potential explanation of the role of clozapine
during SARS-CoV-2 infection that looks at its potential immune-
modulatory role.
An association has been suggested between severe COVID-19 and
lymphopenia (lymphocytes values < 1.5  109/l; 33–83%) (Fan et al.,
2020), with a higher neutrophil to lymphocyte ratio (NLR) (Liu et al.,
2020), predicting disease progression and likely poorer outcomes in
COVID-19 pneumonia (Henry et al., 2020; Gee and Taylor, 2020).
Admission lymphopenia and neutrophilia have also been reported as
predictors of COVID-19 severity and mortality (Henry et al., 2020). On
the contrary, in our sample a significant decrease in the ANC between the
baseline and the time of SARS-CoV-2 infection was observed. It may be
too speculative to claim that clozapine might act as a modulating factor
against severe outcome of COVID-19, by reducing the ratio neu-
trophils/lymphocytes at the time of the SARS-Cov-2 infection. However,
there is evidence that clozapine has immunosuppressant and
pro-inflammatory effects at high doses (Clark et al., 2018) and there are
suggestions that clozapine may also work on immunomodulation rather
than neuromodulation only (Pandarakalam, 2020; Røge et al., 2012).
Notably, fluvoxamine (Lenze al., 2020), chlorpromazine (Plaze et al.,
2020), valproic acid (Bhargava et al., 2020; Singh and Singh, 2020) and
lithium (Murru et al., 2020) have recently been repurposed as potential
immunomodulators in COVID-19 treatment. Conversely, inflammation
has the potential to precipitate clozapine toxicity (Cranshaw and Har-
ikumar, 2020), due to cytokines which cause CYP1A2 enzymes’ inhibi-
tion and increase levels of clozapine plasma concentration (Pfuhlmann
et al., 2009).
At this stage, the correlation between clozapine, SARS-CoV-2 and
immunomodulation remains largely unclear. Although current data will
need to be replicated in larger samples, this report may still help clini-
cians in focusing on a range of relevant issues, including: 1) there may be
a significant drop in ANC during infection with COVID-19 for patients
taking clozapine; 2) the drop may, in some cases, be so significant as to
change the monitoring status from ‘green’ to ‘amber’, giving rise to3
queries and concerns amongst clinicians about whether to continue
clozapine treatment; 3) closely monitoring the outcome of COVID -19
infection is of paramount importance, as it is likely that once this is
resolved the ANC will return to normal range.Declaration of competing interest
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